HC Wainwright Forecasts Higher Earnings for UroGen Pharma

UroGen Pharma Ltd. (NASDAQ:URGN) – Equities research analysts at HC Wainwright increased their FY2024 earnings estimates for UroGen Pharma in a research report issued to clients and investors on Thursday, November 7th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($3.01) per share for the year, up from their previous forecast of ($3.41). HC Wainwright has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for UroGen Pharma’s current full-year earnings is ($3.21) per share. HC Wainwright also issued estimates for UroGen Pharma’s Q4 2024 earnings at ($0.65) EPS, Q1 2025 earnings at ($0.83) EPS, Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.74) EPS, Q4 2025 earnings at ($0.70) EPS and FY2025 earnings at ($3.06) EPS.

Other equities research analysts also recently issued reports about the stock. EF Hutton Acquisition Co. I raised shares of UroGen Pharma to a “strong-buy” rating in a report on Monday, October 14th. Guggenheim initiated coverage on shares of UroGen Pharma in a research note on Thursday, August 22nd. They set a “buy” rating and a $40.00 price objective for the company. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $40.00 price objective on shares of UroGen Pharma in a research note on Wednesday, October 16th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $48.38.

UroGen Pharma Price Performance

Shares of NASDAQ URGN opened at $12.79 on Monday. UroGen Pharma has a twelve month low of $10.60 and a twelve month high of $20.70. The company has a current ratio of 9.00, a quick ratio of 7.93 and a debt-to-equity ratio of 4.77. The company has a market capitalization of $299.93 million, a price-to-earnings ratio of -3.85 and a beta of 1.12. The firm has a 50-day moving average of $12.75 and a two-hundred day moving average of $14.17.

UroGen Pharma (NASDAQ:URGN) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.55) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.29. The business had revenue of $25.20 million during the quarter, compared to analyst estimates of $24.22 million. During the same period in the previous year, the company posted ($0.68) earnings per share.

Institutional Trading of UroGen Pharma

A number of hedge funds have recently bought and sold shares of URGN. China Universal Asset Management Co. Ltd. lifted its stake in UroGen Pharma by 90.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock valued at $103,000 after buying an additional 3,856 shares in the last quarter. Intech Investment Management LLC acquired a new position in shares of UroGen Pharma in the 3rd quarter valued at about $155,000. SG Americas Securities LLC acquired a new position in shares of UroGen Pharma in the 3rd quarter valued at about $179,000. ProShare Advisors LLC acquired a new position in shares of UroGen Pharma in the 2nd quarter valued at about $199,000. Finally, GSA Capital Partners LLP acquired a new position in shares of UroGen Pharma in the 3rd quarter valued at about $249,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.